These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30126704)

  • 1. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
    Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
    Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
    Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS
    Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
    Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
    Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.
    Liberale G; Pop CF; Polastro L; Kerger J; Moreau M; Chintinne M; Larsimont D; Nogaret JM; Veys I
    J Visc Surg; 2020 Apr; 157(2):79-86. PubMed ID: 31837942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
    Kahn RM; McMinn E; Yeoshoua E; Boerner T; Zhou Q; Iasonos A; Long Roche K; Zivanovic O; Gardner GJ; Sonoda Y; O'Cearbhaill RE; Grisham RN; Tew W; Jones D; Huang J; Park BJ; Abu-Rustum NR; Chi DS
    Gynecol Oncol; 2023 Mar; 170():46-53. PubMed ID: 36621269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.
    Ren Y; Jiang R; Yin S; You C; Liu D; Cheng X; Tang J; Zang R
    BMC Cancer; 2015 Aug; 15():583. PubMed ID: 26268818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.